# Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

> **NCT02860000** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 96 (actual)

## Conditions studied

- Estrogen Receptor Status
- HER2/Neu Negative
- Invasive Breast Carcinoma
- Postmenopausal
- Stage III Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** Alisertib
- **DRUG:** Fulvestrant
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02860000
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-06
- **Primary completion:** 2022-01-10
- **Final completion:** 2025-02-14
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02860000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02860000, "Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02860000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*